| Literature DB >> 9086130 |
R T Davey1, D G Chaitt, S C Piscitelli, M Wells, J A Kovacs, R E Walker, J Falloon, M A Polis, J A Metcalf, H Masur, G Fyfe, H C Lane.
Abstract
The safety and efficacy were assessed of 5-day cycles of subcutaneous (sc) interleukin-2 (IL-2) every 8 weeks in human immunodeficiency virus type 1-infected outpatients with >200 CD4 cells/mm3. Immunologic, virologic, and toxicity parameters were measured in 18 patients receiving standard antiretrovirals plus 5-day courses of sc IL-2 (3-18 MIU/day) every 2 months. Systemic toxicities established the maximally tolerated dose (MTD) of IL-2 as 15 MIU/day. CD4 cell responses appeared to correlate directly with baseline CD4 cell counts, with several patients experiencing a dramatic rise after 3 cycles. Virus load increased only transiently in the peri-injection period. It was concluded that serial cycles of outpatient sc IL-2 can be administered safely, with an MTD of 15 MIU/day. Patients with higher baseline counts appear to have a greater CD4 cell response to sc IL-2 therapy.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9086130 DOI： 10.1086/513971
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226